Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HCAR3 | P49019 | 11/20 | 0.58 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.52 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28909765 | 0.98 | POLB (0.62) | CASP6POLBMEN1KMT2ATSHR | |
| SCHEMBL7591997 | 0.87 | CASP6 (0.64) | CASP6POLBMEN1KMT2ATSHR | |
| SCHEMBL20572634 | 0.85 | POLB (0.62) | CASP6POLBMEN1KMT2ATSHR | |
| SCHEMBL3530451 | 0.85 | VCAM1 (0.71) | CASP6POLBMEN1KMT2ATSHR | |
| SCHEMBL6003204 | 0.85 | POLB (0.62) | CASP6POLBMEN1KMT2ATSHR | |
| SCHEMBL9183692 | 0.85 | POLB (0.62) | CASP6POLBMEN1KMT2ATSHR | |
| SCHEMBL9658195 | 0.83 | POLB (0.56) | CASP6POLBMEN1KMT2ATSHR | |
| SCHEMBL9499862 | 0.83 | POLB (0.59) | CASP6POLBMEN1KMT2ATSHR | |
| SCHEMBL19071961 | 0.81 | VCAM1 (0.79) | POLBLMNAVCAM1 | |
| SCHEMBL9658192 | 0.80 | POLB (0.56) | CASP6POLBMEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3408257-B1 | LINKER MOLECULE AND USE OF IT IN PROCESS FOR PURIFICATION OF PEPTIDES | Belyntic GmbH (DE) | 2021-12-22 | — | — | EP | disclosed |
| EP-3408257-A1 | LINKER MOLECULE AND USE THEREOF IN METHODS FOR PURIFYING PEPTIDES | Belyntic GmbH (DE) | 2018-12-05 | — | — | EP | disclosed |
| US-20170283787-A1 | METHOD FOR NON-ENZYMATIC COMBINATION OF NUCLEIC ACID CHAINS | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2017-10-05 | — | — | US | disclosed |
| WO-2017129818-A1 | LINKER MOLECULE AND USE THEREOF IN METHODS FOR PURIFYING PEPTIDES | HUMBOLDT-UNIVERSITÄT ZU BERLIN (DE) | 2017-08-03 | — | — | WO | disclosed |
| EP-3187584-A1 | METHOD FOR NON-ENZYMATIC COMBINATION OF NUCLEIC ACID CHAINS | Japan Science and Technology Agency (JP) | 2017-07-05 | — | — | EP | disclosed |
| US-5378704-A | Non-peptidic angiotensin-II-receptor-antagonists | E. R. SQUIBB & SONS, INC. (US) | 1995-01-03 | — | — | US | disclosed |
| US-4029643-A | Chromium containing azo dyes | NIPPON KAYAKU KABUSHIKI KAISHA (JA) | 1977-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283787-A1 | METHOD FOR NON-ENZYMATIC COMBINATION OF NUCLEIC ACID CHAINS | RNGTT, POLRMT, DNTT | CASP6 2066/4885POLB 8/4885MEN1 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.